MaxCyte, Inc.
MXCTHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeMaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. At a $144.5M market cap, MaxCyte, Inc. ranks as a micro-cap company within healthcare. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Market Cap
$144.5M
Beta
1.49
P/E (TTM)
—
P/E (Fwd)
-5.68
EPS (TTM)
$-0.34
EPS (Fwd)
$-0.25
ROE
-20.4%
ROA
-10.6%
Cash
$105.7M
Total Debt
$17.3M
Free CF
-$13.1M
52W Change
-9.1%
Annual Financials
Cash vs Debt
Where MXCT stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, MXCT finished 20.37% above its 150-day moving average ($1.08) and 22.64% above its 200-day moving average ($1.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MXCT overbought or oversold?
At the October 19, 2026 close, MXCT's RSI(14) was 61.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $105.7M in cash and $17.3M in debt, MXCT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$13.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -20.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $44.3M (2022) to $33.0M (2025), a 25% decline worth watching.
With cash comfortably exceeding debt, MXCT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MXCT.